You are here: Home: CACU 1 | 2007: Peter M. Ravdin, MD, PhD
PUBLICATIONS DISCUSSED BY PETER M RAVDIN, MD, PHD
Ravdin PM et al. A sharp decrease in breast cancer incidence in the United States in
2003. San Antonio Breast Cancer Symposium 2006;Abstract 5.
Mamounas E et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5
years of tamoxifen (TAM): Intent-to-treat analysis of NSABP B-33. San Antonio Breast
Cancer Symposium 2006;Abstract 49.
Dowsett M et al. Relationship between quantitative ER and PgR expression and
HER2 status with recurrence in the ATAC trial. San Antonio Breast Cancer Symposium
2006;Abstract 48.
Muss HB et al. The benefits of letrozole in postmenopausal women with early stage
breast cancer who have had five years of tamoxifen are independent of age. San Antonio
Breast Cancer Symposium 2006;Abstract 102.
Cuzick J et al. A detailed analysis of the benefits of anastrozole over tamoxifen for
venous thromboembolic events (VTEs) after 5 years treatment. San Antonio Breast
Cancer Symposium 2006;Abstract 104.
Brufsky A et al. An integrated analysis of zoledronic acid (ZA) for prevention of aromatase
inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with
early breast cancer (BCa) receiving adjuvant letrozole (LET). San Antonio Breast Cancer
Symposium 2006;Abstract 107.
Singh S et al. Effect of anastrozole on cholesterol fractions in postmenopausal women
with high risk of breast cancer: Results from IBIS-II breast cancer prevention study.
San Antonio Breast Cancer Symposium 2006;Abstract 1055.
McCloskey E et al. Complete data from the letrozole (L), exemestane (E), and anastrozole
(A) pharmacodynamic (PD) LEAP trial: Direct comparison of safety parameters
between aromatase inhibitors (AIs) in healthy postmenopausal women. San Antonio
Breast Cancer Symposium 2006;Abstract 2092.
Partridge AH et al. Adherence with adjuvant anastrozole therapy among women with
early stage breast cancer. San Antonio Breast Cancer Symposium 2006;Abstract 4044.
Duffy S et al. Anastrozole is associated with a lower risk of endometrial abnormalities
than tamoxifen: First report of the ATAC trial endometrial sub-protocol at 6 years
follow-up. San Antonio Breast Cancer Symposium 2006;Abstract 4055.
Van Poznak C et al. The SABRE (study of anastrozole with the bisphosphonate risedronate)
study: The effects of risedronate on BMD and bone metabolism in postmenopausal
women using anastrozole as adjuvant therapy for hormone receptor-positive
early breast cancer — First results. San Antonio Breast Cancer Symposium
2006;Abstract 4061.
Baehner FL et al. Quantitative RT-PCR analysis of ER and PR by Oncotype DX
indicates distinct and different associations with prognosis and prediction of tamoxifen
benefit. San Antonio Breast Cancer Symposium 2006;Abstract 45.
Watson D et al. The impact on the recurrence score due to patient variation in the
quantitative expression of individual genes or gene groups. San Antonio Breast Cancer
Symposium 2006;Abstract 6039.
Shak S et al. Relationship between proliferation genes and expression of hormone and
growth factor receptors: Quantitative RT-PCR in 10,618 breast cancers. San Antonio
Breast Cancer Symposium 2006;Abstract 6111.
Shak S et al. Subtypes of breast cancer defined by standardized quantitative RT-PCR
analysis of 10,618 tumors. San Antonio Breast Cancer Symposium 2006;Abstract 6118.
|
